In a multicenter , double-blind , randomized study , 131 patients with quiescent UC were assigned to two groups : 65 to receive a pH-dependent release formulation of mesalamine at 2.4 g/day ( pH-2 .4 g ) and 66 to receive a time-dependent release formulation of mesalamine at 2.25 g/day ( Time-2 .25 g ) .
